Lenvatinib in Management of Solid Tumors.

Lenvatinib in Management of Solid Tumors. Oncologist. 2019 Oct 14;: Authors: Hao Z, Wang P Abstract Lenvatinib is a type I tyrosine kinase inhibitor exhibiting powerful antiangiogenic activity in cancer therapy. Displaying activity in multiple solid tumors, it has been approved in differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma as single agent or in combination. In addition, lenvatinib has shown promise in several other tumor types including medullary, anaplastic thyroid, adenoid cystic, and endometrial cancer. Exploring synergy between angiogenic and immune checkpoint inhibitors, the lenvatinib/pembrolizumab combination is poised to become the next pair of active drugs in endometrial, lung, and gastrointestinal malignancies. Despite robust activity, the drug can be difficult to tolerate. Optimization of dose and biomarkers for prediction of efficacy and toxicities will be of great help. IMPLICATIONS FOR PRACTICE: Readers will be presented with an update on U.S. Food and Drug Administration approval of lenvatinib and suggestions for off-label use in thyroid cancer and adenoid cystic carcinomas. They will become familiarized with the common side effects, frequency, and predicators of response. In addition, they will learn that different strengths of lenvatinib are prescribed and why. Finally, readers are pointed to the latest efforts to combine lenvatinib and pembrolizumab, as well as to unresolved issues such as long-ter...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research

Related Links:

Conclusions: The caregivers of patients with cancer or chronic severe illnesses experience high levels of fatigue: the longer the disease duration, the greater the degrees of depression, anxiety, and physical fatigue experienced by the caregivers. Such caregivers need strategies to manage their fatigue and depression. PMID: 32963657 [PubMed - in process]
Source: Pain Research and Management - Category: Anesthesiology Authors: Tags: Pain Res Manag Source Type: research
Authors: Chen P, Wang H, Li M, Yang L, Mou F, Singh B, He JY, Zhang W Abstract 6,12-Diphenyl-3,9-diazatetraasterane-1, 5, 7, 11-tetracarboxylate (DDTC) has been synthesized by the photodimerization of 4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate. The potential of theercvantitumor activity and mechanism were investigated in vitro using MTT assay in human lung cancer cell line A549, ovarian cancer cell lines SKOV3 and A2780, breast cancer cell line MCF-7, gastric cancer cell line BGC-823, colon cancer cell line HT29, prostate cancer cell line DU145, and liver cancer cell line SMMC7721. The results show that DDTC ca...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Authors: Lin N, Li J, Ke Q, Wang L, Cao Y, Liu J Abstract Aim: To evaluate the prognostic significance of C-reactive protein to albumin ratio (CAR) for clinical outcomes in hepatocellular carcinoma (HCC) patients. Material and Methods. Eligible studies were searched by PubMed, MedLine, the Cochrane Library, from January 1, 2000, to June 30, 2019, investigating the prognostic value of CAR in patients with HCC. Primary endpoint was OS. Hazard ratio (HR) with 95% confidence interval (CI) was used to determine the effect size. Results: 7 records including 2208 patients published since 2014 were enrolled into our me...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Authors: Park SK, Park JA, Yang SY, Shin JY, Koh H Abstract Objectives: Recognizing the value of anticancer treatments based on progression-free survival and overall survival may help decision making in healthcare policy. We aimed to measure and compare the impact of disease progression and terminal state prior to death on healthcare costs in HR+, HER2- ABC patients.Methods: We conducted a retrospective study using Korean nationwide health insurance claims database between 9/1/2012-8/31/2017. The impact of disease progression was estimated by measuring the average incremental monthly cost per patient during 1 year ...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
This study aims to explore the relationship between the expression levels of genes involved in the PD-L1 pathway and radiosensitivity for gastric cancer patients. A total of 367 patients with clinical survival information and radiotherapy information were obtained in The Cancer Genome Atlas (TCGA). Genes involved in the PD-L1 pathway were categorized into high and low expression level groups according to the median value. The Cox proportional hazards model was used to find the association between gene expression level and radiosensitivity. The results show that high expression levels of CD274, EGFR, RAF1, RPS6KB1, PIK3CA, ...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Conclusion: Neoadjuvant CCRT achieved more favorable OS and PFS than did neoadjuvant chemotherapy alone, without significant increases of toxicity in patients. However, prospective randomized trials comparing treatment modalities are necessary to confirm the potential advantages of neoadjuvant CCRT. PMID: 32963531 [PubMed]
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Abstract In various cancers, high-grade tumor and poor survival rate in patients with upregulated lncRNAs UCA1 have been confirmed. Urothelial carcinoma associated 1 (UCA1) is an oncogenic non-coding RNA with a length of more than 200 nucleotides. The UCA1 regulate critical biological processes that are involved in cancer progression, including cancer cell growth, invasion, migration, metastasis, and angiogenesis. So It should not surprise that UCA1 overexpresses in variety of cancers type, including pancreatic cancer, ovarian cancer, gastric cancer, colorectal cancer, breast cancer, prostate cancer, endometrial c...
Source: Current Molecular Medicine - Category: Molecular Biology Authors: Tags: Curr Mol Med Source Type: research
Conclusions: MDCT scanning is accurately imaging modality for the evaluation of synchronous lymphoma and other solid malignancies. More reports and accumulation of such cases should help to clarify the mechanisms, contribute to a further understanding of this phenomenon, and may lead to a new treatment strategy for synchronous lymphoma and other solid malignancies.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
In a recently published paper in theAnnals of Oncology [1], Choi et al. evaluated the strength of the evidence in the literature for the association between body mass index and 20 cancers in a manner that resembles our umbrella review on the same topic [2]. We were surprised to see that there were many discrepancies between the two assessments. The current paper used a grading scheme consisting of similar criteria used in our umbrella review, but structured the grading differently without providing a justification for this choice. Our umbrella review used a grading scheme that has been extensively applied and justified in ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Publication date: 20 July 2015 Source:Clinica Chimica Acta, Volume 447 Author(s): Bin Wei , Chunmei Guo , Shuqing Liu , Ming-Zhong Sun Annexin A4 (Anxa4) is one of the Ca2+-regulated and phospholipid-binding annexin superfamily proteins. Anxa4 has a potential role in diagnosis, prognosis, and treatment of certain cancers. Studies indicate that Anxa4 up-regulation promotes the progression of tumor and chemoresistance of colorectal cancer (CRC), esophageal squamous cell carcinoma (ESCC), endometrial carcinoma (EC), gastric cancer (GC), chemoresistant lung cancer (LC), malignant mesothelioma (MM), renal cell carcinoma (RCC)...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
More News: Adenoids | Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Endometrial Cancer | Food and Drug Administration (FDA) | Gastroenterology | Hepatocellular Carcinoma | Kidney Cancer | Learning | Liver Cancer | Renal Cell Carcinoma | Thyroid | Thyroid Cancer | Toxicology | Universities & Medical Training